Brief: Somalogic Enters Into 2nd Amendment To Master Collaboration Agreement With Novartis Pharma AG
10/01/2023 21:26
Jan 10 (Reuters) - Somalogic Inc SLGC.O :
* SOMALOGIC INC - ON JAN 4, CO'S UNIT, ENTERED INTO
AMENDMENT #2
TO MASTER COLLABORATION AGREEMENT WITH NOVARTIS PHARMA AG
* SOMALOGIC INC - AMENDMENT AMENDS THE MASTER COLLABORATION
AGREEMENT, DATED AS OF SEPTEMBER 20, 2019, BY AND BETWEEN CO'S
UNIT AND NOVARTIS
* SOMALOGIC - AMENDMENT EXTENDS TERM OF AGREEMENT FOR
COMPANY TO
REMAIN NOVARTIS’ PRIMARY PROTEOMICS PLATFORM PROVIDER THROUGH
DEC 31, 2033
Source: (shorturl.at/qAY29)
Further company coverage: SLGC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Somalogic
See all newsBrief: Somalogic Stockholders Vote To Approve Standard Biotools Transaction At Special Meeting
Brief: Madryn Asset Management Demands Somalogic’S Board Address Repeated, Unprecedented Adjournments Of Tainted Special Meeting
Brief: Madryn Asset Management Says It Urges All Somalogic Shareholders To Oppose Transaction With Standard Biotools
Brief: Madryn Asset Management Urges Shareholders To Vote “Against” The Proposed Merger And Allow Somalogic To Pursue Value-Enhancing Alternatives
Brief: Somalogic Board Reiterates Value-Maximizing Transaction With Standard Biotools Is In Best Interests Of All Stockholders